Medtronic, Inc. Resolute(R) Drug-Eluting Stent Shows Superiority to Taxus(R) DES in Study of Patients with Coronary Artery Disease

MINNEAPOLIS--(BUSINESS WIRE)--The Resolute® drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), showed superiority to Boston Scientific Corp.’s Taxus® DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.